Skip to main content

Advertisement

SpringerLink
Log in

Interventions for body habitus changes associated with HIV infection and its treatment

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Lipodystrophy and its two components lipo-accumulation and lipoatropy are very common among individuals with HIV infection on treatment, especially among those who started therapy in the late 1990s and early 2000s. This review discusses the current management of these complications of HIV and its treatment. For the purpose of clarity in this review, we have divided the interventions according to the predominant phenotype of the individual.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mallon PW, Miller J, Cooper DA, Carr A: Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003, 17:971–979.

    Article  PubMed  CAS  Google Scholar 

  2. Dube MP, Parker RA, Tebas P, et al.: Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005, 19:1807–1818.

    Article  PubMed  CAS  Google Scholar 

  3. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51–58.

    Article  PubMed  CAS  Google Scholar 

  4. Bacchetti P, Gripshover B, Grunfeld C, et al.: Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40:121–131.

    Article  PubMed  Google Scholar 

  5. Hansen AB, Lindegaard B, Obel N, et al.: Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. HIV Med 2006, 7:38–45.

    Article  PubMed  CAS  Google Scholar 

  6. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191–201.

    Article  PubMed  CAS  Google Scholar 

  7. Miller J, Carr A, Emery S, et al.: HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003, 4:293–301.

    Article  PubMed  CAS  Google Scholar 

  8. Carr A, Emery S, Law M, et al.: An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003, 361:726–735.

    Article  PubMed  CAS  Google Scholar 

  9. Yarasheski KE, Tebas P, Stanerson B, et al.: Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J Appl Physiol 2001, 90:133–138.

    PubMed  CAS  Google Scholar 

  10. Driscoll SD, Meininger GE, Ljungquist K, et al.: Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2004, 89:2171–2178.

    Article  PubMed  CAS  Google Scholar 

  11. Jones SP, Doran DA, Leatt PB, et al.: Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 2001, 15:2049–2051.

    Article  PubMed  CAS  Google Scholar 

  12. Roubenoff R, Schmitz H, Bairos L, et al.: Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis 2002, 34:390–393.

    Article  PubMed  Google Scholar 

  13. Thoni GJ, Fedou C, Brun JF, et al.: Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab 2002, 28:397–404.

    PubMed  CAS  Google Scholar 

  14. Fitch K, Anderson E, Hubbard J, et al.: Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome [abstract 24]. Presented at the 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Francisco, CA; September 24–26, 2006.

  15. Amorosa V, Synnestvedt M, Gross R, et al.: A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005, 39:557–561.

    PubMed  Google Scholar 

  16. Barrios A, Blanco F, Garcia-Benayas T, et al.: Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 2002, 16:2079–2081.

    Article  PubMed  Google Scholar 

  17. Engelson ES, Glesby MJ, Mendez D, et al.: Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 2002, 30:379–391.

    PubMed  CAS  Google Scholar 

  18. Tai VW, Schambelan M, Algren H, et al.: Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis 2002, 35:1258–1262.

    Article  PubMed  CAS  Google Scholar 

  19. Kotler DP, Muurahainen N, Grunfeld C, et al.: Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004, 35:239–252.

    Article  PubMed  CAS  Google Scholar 

  20. Lo JC, Mulligan K, Noor MA, et al.: The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001, 86:3480–3487.

    Article  PubMed  CAS  Google Scholar 

  21. Lo JC, Mulligan K, Noor MA, et al.: The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin Infect Dis 2004, 39:732–735.

    Article  PubMed  CAS  Google Scholar 

  22. Falutz J, Allas S, Kotler D, et al.: A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005, 19:1279–1287.

    Article  PubMed  CAS  Google Scholar 

  23. Hadigan C, Corcoran C, Basgoz N, et al.: Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000, 284:472–477.

    Article  PubMed  CAS  Google Scholar 

  24. Hadigan C, Meigs JB, Rabe J, et al.: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001, 86:939–943.

    Article  PubMed  CAS  Google Scholar 

  25. Mulligan K, Yang Y, Wininger DA, et al.: Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 2007, 21:47–57.

    Article  PubMed  CAS  Google Scholar 

  26. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.

    Article  PubMed  CAS  Google Scholar 

  27. Drechsler H, Powderly WG: Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002, 35:1219–1230.

    Article  PubMed  CAS  Google Scholar 

  28. Teppler H, Azrolan N, Chen J, Nguyen BY: Differential effect of MK-0518 and efavirenz on serum lipids and lipoproteins in antiretroviral therapy (ART)-naive patients [abstract H-0256a]. In Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 17–20, 2006.

  29. Piliero PJ, Hubbard M, King J, Faragon JJ: Use of ultrasonography-assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad. Clin Infect Dis 2003, 37:1374–1377.

    Article  PubMed  CAS  Google Scholar 

  30. Gervasoni C, Ridolfo AL, Vaccarezza M, et al.: Long-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapy. AIDS 2004, 18:574–576.

    Article  PubMed  Google Scholar 

  31. Strub C, Kaufmann GR, Flepp M, et al.: Gynecomastia and potent antiretroviral therapy. AIDS 2004, 18:1347–1349.

    Article  PubMed  Google Scholar 

  32. Walker UA, Venhoff N, Koch EC, et al.: Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003, 8:463–470.

    PubMed  CAS  Google Scholar 

  33. Banasch M, Goetze O, Knyhala K, et al.: Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients. AIDS 2006, 20:1554–1556.

    Article  PubMed  CAS  Google Scholar 

  34. Sutinen J, Walker UA, Sevastianova K, et al.: Uridine supplementation increases subcutaneous fat in patients with HAART-associated lipodystrophy a randomized, placebocontrolled trial [abstract 7]. In Program and Abstracts of the 7th International Workshop on Adverse Events and Lipodystrophy in HIV. Dublin, Ireland; November 13–16, 2005.

  35. McComsey GA, O’Riordan M, Setzer B, et al.: Effect of Nucleomaxx on fat and blood mitochondrial DNA in D4T-treated subjects with clinical lipoatrophy. Antivir Ther 2005, 10(Suppl 3):L49.

    Google Scholar 

  36. Arioglu E, Duncan-Morin J, Sebring N, et al.: Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000, 133:263–274.

    PubMed  CAS  Google Scholar 

  37. Sutinen J, Hakkinen AM, Westerbacka J, et al.: Rosiglitazone in the treatment of HAART-associated lipodystrophy—a randomized double-blind placebo-controlled study. Antivir Ther 2003, 8:199–207.

    PubMed  CAS  Google Scholar 

  38. Hadigan C, Yawetz S, Thomas A, et al.: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Medicine 2004, 140:786–794.

    CAS  Google Scholar 

  39. Carr A, Workman C, Carey D, et al.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004, 363:429–438.

    Article  PubMed  CAS  Google Scholar 

  40. Slama L, Lanoy E, Valentin MA, et al.: Effect of pioglitazone on HIV-1 lipoatrophy: a randomised, double-bind, placebocontrolled trial (ANRS 113) [abstract 151LB]. Presented at the 13th Conference on Retrovirus and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  41. Milinkovic A, Lopez S, Vidal S, et al.: A randomized open study comparing the effect of reducing stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine [abstract 857]. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.

  42. Carr A, Workman C, Smith DE, et al.: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002, 288:207–215.

    Article  PubMed  CAS  Google Scholar 

  43. Martin A, Smith DE, Carr A, et al.: Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004, 18:1029–1036.

    Article  PubMed  CAS  Google Scholar 

  44. McComsey GA, Ward DJ, Hessenthaler SM, et al.: Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis 2004, 38:263–270.

    Article  PubMed  CAS  Google Scholar 

  45. Moyle GJ, Sabin CA, Cartledge J, et al.: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006, 20:2043–2050.

    Article  PubMed  CAS  Google Scholar 

  46. Boyd MA, Bien D, Ruxrungtham K, et al.: Reversal of mitochondrial DNA and RNA depletion in patients switched to indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd after failing NRTI combination therapy: a prospective, 48 week substudy of HIV-NAT 009 [abstract WePpB2064]. Presented at the XV International AIDS Conference. Bangkok, Thailand; July 11–16, 2004.

  47. Tebas P, Zhang J, Yarasheski K, et al.: Switch to a protease inhibitor-containing/nucleoside reverse transcriptase inhibitor-sparing regimen increases appendicular fat and serum lipid levels without affecting glucose metabolism or bone mineral density. The results of a prospective randomized trial, ACTG 5125s [abstract 40]. Presented at the 12th Conference on Retrovirus and Opportunistic Infections. Boston, MA; February 22–25, 2005.

  48. Murphy R, Zhang J, Hafner R, et al.: Peripheral and visceral fat changes following a treatment switch to a nonthymidine analogue or nucleoside-sparing regimen in patients with peripheral lipoatrophy: 48-week final results of ACTG A5110, a prospective, randomized multicenter clinical trial [abstract 755]. Paper presented at the 13th Conference on Retrovirus and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  49. Valantin MA, Aubron-Olivier C, Ghosn J, et al.: Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003, 17:2471–2477.

    Article  PubMed  CAS  Google Scholar 

  50. Moyle GJ, Lysakova L, Brown S, et al.: A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004, 5:82–87.

    Article  PubMed  CAS  Google Scholar 

  51. Perry CM: Poly-L-lactic acid. Am J Clin Dermatol 2004, 5:361–368.

    Article  PubMed  Google Scholar 

  52. Humble G, Mest D: Soft tissue augmentation using sculptra. Facial Plast Surg 2004, 20:157–163.

    Article  PubMed  Google Scholar 

  53. Lafaurie M, Dolivo M, Porcher R, et al.: Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr 2005, 38:393–398.

    Article  PubMed  CAS  Google Scholar 

  54. Silvers SL, Eviatar JA, Echavez MI, Pappas AL: Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 2006, 118(3 Suppl):34S–45S.

    Article  PubMed  CAS  Google Scholar 

  55. Serra-Renom JM, Fontdevila J: Treatment of facial fat atrophy related to treatment with protease inhibitors by autologous fat injection in patients with human immunodeficiency virus infection. Plast Reconstr Surg 2004, 114:551–556.

    Article  PubMed  Google Scholar 

  56. Guaraldi G, De Fazio D, Orlando G, et al.: Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. Clin Infect Dis 2005, 40:e13–15.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AIDS Clinical Research Unit, University of Pennsylvania, 3451 Walnut Street, Philadelphia, PA, 19104, USA

    Pablo Tebas MD

Authors
  1. Pablo Tebas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pablo Tebas MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tebas, P. Interventions for body habitus changes associated with HIV infection and its treatment. Curr HIV/AIDS Rep 4, 86–92 (2007). https://doi.org/10.1007/s11904-007-0013-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-007-0013-x

Keywords

Search

Navigation